Research sheds light on how muscle fibres degenerate in Duchenne Muscular Dystrophy

1 Oct 2018, 3:56 p.m.

Test tubes on a revolving plate in a lab

A novel cell death process known as necroptosis is responsible for the degeneration of muscle cells over time in Duchenne muscular dystrophy (DMD), according to new research from the National Institute for Health Research (NIHR) Great Ormond Street Hospital (GOSH) Biomedical Research Centre.  DMD, a serious neuromuscular condition that affects one in 5000 boys, is caused by errors in the dystrophin gene. This life-limiting condition causes muscle cells to be lost over time and scar tissue to build up making movement increasingly difficult.

In this study, researchers based at GOSH and the UCL Great Ormond Street Institute of Child Health (ICH) found that necroptosis, a newly-described mechanism of controlled cell death, plays a major role in the death of muscle fibres in dystrophin-deficient cells studied in the lab.

This research, led by Dr Maximilien Bencze, Research Associate at the Dubowitz Neuromuscular Centre at ICH, found that a protein called RIPK3 was involved in regulating death of muscle cells over time. They also found that less muscle cells die when RIPK3 was absent, pointing to a potential target for DMD therapies in the future. This cell death mechanism may also be involved in other neuromuscular disorders and this will be tested in future research.

The research was published in Nature Communications.

Work using human tissue samples was supported by NIHR via the GOSH BRC

Fourth Annual NIHR GOSH BRC Image Competition - A Moment of Discovery

The Research and Innovation Communications team at GOSH and the NIHR GOSH Biomedical Research team invite you to enter our Research and Innovation Showcase: A Moment of Discovery.

New hope to prevent blindness in children with rare genetic disease

A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialled by Clinicians at GOSH and University College London Great Ormond Street Institute of Child Health (UCL GOS ICH).

GOSH only hospital outside of North America to receive innovation funding award for AI

GOSH has been awarded the Amazon Web Services IMAGINE Grant: Children’s Health Innovation Award, to support artificial intelligence (AI) development and drive progress for children’s healthcare.

New clinical trial at GOSH gives hope to children with aggressive blood cancer

Researchers at GOSH and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) are collaborating on a novel approach to clinical trials to give hope to children with an aggressive type of blood cancer, T-cell acute lymphoblastic leukaemia (T-ALL)